Allergan Provides Board and Annual Shareholder Meeting Updates

DUBLIN, Feb. 3, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today provided an update on its Board of Directors and set the record date and the meeting date for its 2017 Annual General Meeting of Shareholders.

Allergan's Board of Directors elected Adriane M. Brown as a new director. The Company had previously announced that Brown would join the Board beginning in February 2017. Ms. Brown is currently President and Chief Operating Officer of Intellectual Ventures LLC, a private global invention company focused on providing access to valuable patents and invention related services. Ms. Brown has served on the Board of Directors of Harman International Industries, Inc. since June 2013, where she is a member of the Compensation Committee and the Technology and Innovation Committee.

"Adriane's 30-year track record of management leadership and public board experience make her an exceptional fit to support Allergan's focus on innovation and growth," said Brent Saunders, Chairman, CEO and President of Allergan.

Separately, Allergan announced that Michael R. Gallagher will be retiring from its Board of Directors, and therefore will not stand for re-election at the 2017 Annual General Meeting of Shareholders. Gallagher has served as a director since March 2015. He previously served on the Allergan, Inc. Board of Directors from 1998 until Allergan, Inc. was acquired by Actavis plc. In 2004, Mr. Gallagher retired as Chief Executive Officer and as a Director of Playtex Products, Inc.  

"We thank Mike for his tremendous service and commitment to Allergan over the course of nearly two decades. During that time Allergan experienced significant growth and was transformed into a leading biopharmaceutical company. We wish him and his family all the best in his retirement," said Saunders.

Allergan also announced that its 2017 Annual General Meeting of Shareholders will be held on May 4, 2017 in Dublin, Ireland. The Company also announced that its Board of Directors has set the close of business on March 8, 2017 as the record date for determining shareholders eligible to vote at the meeting.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Allergan plc

Related Links

http://www.allergan.com